Identification of novel therapies for MLL-rearranged leukemia

Using a fruit fly model of MLL-rearranged leukemia to map the weak points of the disease, which can be targeted by novel treatments

 

Chromosomal rearrangements of the MLL gene are associated with development of high-risk acute leukemia that occurs in both children and adults. MLL-rearranged (MLL-r) leukemia is treated with aggressive chemotherapy, but patients often relapse and survival rates are dismal. Clearly, there exists a need for novel forms of therapy. However, development of new treatment is hampered by our very limited understanding of the genetic framework that underpins MLL-r leukemia.

 Goal

The goal of our research is to unravel the genetic framework underpinning MLL-r leukemia, because exposing the genetic factors that are critical for survival of MLL-r leukemia cells may provide novel inroads for targeted therapy. To reach this goal, we take advantage of the powerful genetic tools of Drosophila melanogaster in a fly model of MLL-r leukemia developed in our lab. In this model, expression of a human leukemic oncogene in the fly hematopoietic system results in hyperproliferation of blood cells that strikingly resembles human leukemia. Using this model, we will first obtain new mechanistic insight into MLL-r biology. We will also use the model for genetic and chemical screening. This work will advance our knowledge of MLL-r leukemia with the ultimate goal of developing new therapies for patients suffering from MLL-r leukemia.

 

What we offer the student

  • Experience with handling and crossing of fruit flies as well as genetic techniques
  • Experience with state-of-the-art microscopy
  • Experience in molecular biology and biochemistry methods: Western blotting,  PCR, cloning, qRT-PCR
  • Training in transferrable skills: presentations, writing, project planning
  • You get to be part of an international research team with researchers at different stages of their careers
  • Frequent opportunities to get input on your data (weekly lab meetings) and to get updated on the most recent advances in our field of interest (“journal club” presentations)
  • We have an ambitious environment where team members share their expertise to help each other get better!

Our research group

 

The “Cancer Molecular medicine” research group is led by Jorrit Enserink and consists of 12 members from 6 different countries. One of our research areas is leukemia and the development of new therapies for AML patients. The group is a young and dynamic environment and has long experience in supervision of master- and PhD students. Our group is part of the Department for Molecular Cell Biology at Radiumhospitalet, where we share facilities, reagents and expertise with other groups working with fruit flies.

Veiledere:

Helene Knævelsrud

Jorrit Enserink

 

Expression of MLL-fusion protein in the fly hematopoietic system results in hyperproliferation of blood cells.

The Enserink group

Image 3:

The supervisors for this project: Helene Knævelsrud and Jorrit Enserink

Published Apr. 19, 2018 8:13 AM - Last modified July 16, 2018 1:05 PM

Supervisor(s)

Scope (credits)

60